In conclusion, our results show that Rho-kinase inhibitors, H1152 and Fasudil, decrease melanoma growth, and pretreatment of B16F10 melanoma cells with H1152 inhibitor promotes an anti-tumor immune response through increased FasL expression. The gene discussed is FASLG; the disease is neoplasm.